We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




World's First Reusable Biochip Architecture Designed

By LabMedica International staff writers
Posted on 07 Jul 2010
The world's first reusable biochip architecture has been developed for the commercial market. More...
These reusable integrated fluidic circuits (IFCs) will dramatically lower single nucleotide phenotype (SNP) genotyping costs and are designed to support accelerated sample throughput, while maintaining data quality of 99.75% or greater accuracy and 99% or greater call rates.

Fluidigm Corp. (South San Francisco, CA, USA) initially invented this architecture to support a progressive new program driven by the Agricultural Research Service (ARS; Washington, DC, USA), the chief scientific research agency of the United States Department of Agriculture (USDA). The program's goal is to drive high sample throughput genotyping down to a penny-per-data-point, which would enable widespread adoption of genetic analysis in vegetable and fruit seeds, livestock (such as cattle, pigs, sheep, poultry), and fishery management. This will significantly improve the quality and quantity of the food supply, while lowering production costs.

Fluidigm's new reuse architecture represents the first step towards making this goal a reality. "We are elated that Fluidigm's reusable biochip can contribute to improving the food supply and bring the benefits of genetic analysis and testing to AgBio scientists and producers around the globe,” said Gajus Worthington, president and chief executive officer of Fluidigm. "A year ago, when we set out to develop a reusable chip, the notion was controversial. But we thought the idea was compelling--and so did our customers. I am so pleased that our scientists and engineers weren't inhibited by traditional thinking that believed reusability in the microfluidic device was impossible. Instead of acquiescing to the norm, they overcame the dogma of the past and achieved an engineering marvel. I believe reusability will be revolutionary for our industry and the life science fields we serve. Reusability lowers costs, eliminates waste, and confers flexibility. I can't think of an invention we've made at Fluidigm that has excited me more.”

Mr. Worthington noted that the company had also recently introduced an ultra-fast thermal cycler--the FC1 Cycler--and is adding a new IFC controller designed to support reusable chips. Initially the reuse family of products will include chips, a new controller, the FC1 Cycler, and either the EP1 Reader or the BioMark system. A new chip and instrument will be announced soon to start high-sample throughput genotyping customers down the reusable path. "We expect to bring additional chip configurations, instruments, and assays to the market place over this year and next that will make reusability practical for more customers, continue to lower costs per data point and set a course for genetic analysis to contribute to a better food supply for the world,” stated Mr. Worthington.

Application of Fluidigm's reuse technology will also contribute to the life-science industry's competitiveness. "We have recently added the Fluidigm system to the family of genomic services we offer our clients. We are seeing a great and growing need for high quality, cost-effective genetic testing services from plant and animal researchers. We have done some work in this area, but cost has always been a barrier. Fluidigm's new reusable chips will enable our agriculture-based customers to realize the tremendous benefits of SNP genotyping at significantly reduced costs,” said Steve McPhail, Expression Analysis's president and chief executive officer. Expression Analysis, Inc. (Durham, NC,USA) is a leading provider of genomic services for clinical trials and research.

Fluidigm develops, manufactures, and markets proprietary IFC systems that significantly improve productivity in life science research. Fluidigm's IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes.

Related Links:

Fluidigm



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.